An Expanded Access Protocol of ATA230 (Third-Party Donor-Derived Cytomegalovirus-Specific T Cells) for the Treatment of CMV Viremia or Disease in Subjects for Whom There Are No Other Comparable Options

Trial Profile

An Expanded Access Protocol of ATA230 (Third-Party Donor-Derived Cytomegalovirus-Specific T Cells) for the Treatment of CMV Viremia or Disease in Subjects for Whom There Are No Other Comparable Options

Suspended
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs ATA 230 (Primary)
  • Indications Cytomegalic inclusion disorders
  • Focus Expanded access; Therapeutic Use
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 09 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top